We can’t show the full text here under this license. Use the link below to read it at the source.
Effect of once‐weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD‐2 clinical trial
Once-weekly dulaglutide versus insulin glargine in type 2 diabetes with different starting blood sugar patterns
AI simplified
Abstract
At 52 weeks, significant reductions in glycated hemoglobin () were observed with dulaglutide 1.5 mg in all glycaemic subgroups except for those with low fasting glucose and low postprandial glucose receiving insulin glargine.
- Dulaglutide stimulates insulin secretion and reduces glucagon levels in a glucose-dependent manner.
- Basal insulin primarily reduces elevated fasting glucose by inhibiting liver glucose production.
- Participants were categorized into four subgroups based on baseline fasting and postprandial glucose levels.
- All subgroups treated with dulaglutide and glargine showed significant HbA1c reductions, except the low FG/low PPG group on glargine.
- Dulaglutide resulted in greater HbA1c reductions compared to glargine across most subgroups.
AI simplified
Key numbers
−1.4%
Reduction
Change from baseline in at 52 weeks for dulaglutide 1.5 mg.
−4.5 kg
Body Weight Change
Change from baseline in body weight for dulaglutide in the low FG/high PPG subgroup.
766
Participants Included
Total number of participants in the post hoc analysis.